Research We Funded

Your generous support enables The ALS Association to fund millions of dollars in research every year, in locations across the globe. From individual projects to global collaborations, we provide funding to experts in a variety of scientific focus areas critical to advancing the search for treatments and a cure for ALS.

Sampling of Grants We Have Funded During the Past 3 Years

Grant ID Project Title Applicant Award Start Date Award End Date Award Amount Primary Organization Program Name
21-SI-569Maintain the SOD1 breeding colony in 2020Torvund-Jensen, Julie02/01/202001/31/2021102600.00Taconic Biosciences, Inc.Strategic Initiative
21-MALS-568Eye Gaze Controlled Neck Brace for ALS Patients with Head DropAgrawal, Sunil02/01/202005/31/2023200000.00The Trustees of Columbia University in the City of New YorkManaging ALS - MALS
20-SI-543Natural History Pilot Project-NUAjroud-Driss, Senda01/01/202006/30/202025659.00Northwestern University - Evanston CampusStrategic Initiative
22-PDF-609An Integrated Genome-Based Approach to Individualised Treatment in ALS and FTDAl Khleifat, Ahmad01/31/202209/30/2023150000.00King's College London, Institute of PsychiatryMilton Safenowitz Postdoctoral Fellowship Program
23-SI-6212022 Holloway Postdoc Fellowship (AFTD/ALS Association)Anderson, Eric07/01/202206/30/202460000.00University of PittsburghStrategic Initiative
20-MALS-555Development and usability of a neuromuscular wearable system to enable reliable caregiver alerts and communication for people with ALSAng, Dexter01/31/202007/31/2022200000.00Pison Technology IncManaging ALS - MALS
20-SI-561Natural History Pilot Project-Henry Ford HealthArcila Londono, Ximena01/01/202009/30/202025659.00Henry Ford Health SystemStrategic Initiative
23-CSDA-6182022 Clinician Scientist Development AwardArnold, Frederick07/01/202206/30/2025168000.00The Regents of the University of California (Irvine)Clinician Scientist Development Award
21-DDC-565Targeting soITNF-dependent inflammation in ALS with XPro1595Barnum, Christopher02/01/202010/31/2022500000.00INmuneBio Inc.The Lawrence and Isabel Barnett Drug Development Award
20-DDC-548Targeting immune-checkpoint pathways: a novel therapeutic approach in ALSBaruch, Kuti01/31/202007/31/2022499413ImmunoBrain Checkpoint, Inc.The Lawrence and Isabel Barnett Drug Development Award
23-SI-622ALSUntangledBedlack, Richard07/01/202206/30/202566614.00Duke UniversityStrategic Initiative
20-SI-563Renewal for 17-CPT-374, The Effects of RNS60 on ALS biomarkersBeghi, Ettore01/01/202006/30/2021283622.00Istituto di Ricerche Farmacologiche Mario Negri (Mario Negri Institute for Pharmacological Research)Strategic Initiative
20-IIA-530Using peripheral macrophages (PM) as a target for ALSBoillee, Severine12/01/201903/31/2023240000Paris Brain Institute (Institut du Cerveau - ICM), CNRS, Inria, Inserm, AP-HP, Sorbonne UniversitéInvestigator-Initiated Multi-year Award
20-SI-545Neurofilament levels in Cytokinetics Vitality Phase III Longitudinal Plasma SamplesBowser, Robert01/31/202005/31/2022154000.00Iron Horse Diagnostics, Inc.Strategic Initiative
22-SI-599The Answer ALS Research Data PortalBoyce, Danielle09/01/202108/31/2023620702.00Johns Hopkins University School of MedicineStrategic Initiative
22-CRTF-595Activity and Regulation of ALS Causing Variants of Kinesin KIF5ABrent , Jonathan07/01/202106/30/2023105000.00Northwestern Memorial HospitalClinical Research Training Fellow
20-SI-562Trial of Dual Function, Gene Silencing-Replacement Therapy in Canine SOD1E40k/E40K ALSBrown, Robert01/31/202006/30/2023420000.00University of Massachusetts Chan Medical SchoolStrategic Initiative
21-IIA-571Determining the Effects of Hexanucleotide Repeat Expansion on RNA Localization and Local TranslationBurguete, Alondra03/01/202011/30/2023300000The Trustees of Columbia University in the City of New YorkInvestigator-Initiated Multi-year Award
22-SI-612Development of skin biomarker for early diagnosis of ALSChen, Shu12/01/202111/30/202260000.00University of Alabama at BirminghamStrategic Initiative
21-DDC-574Copper-ATSM and follistatin: A nerve-muscle combination therapy strategyCrouch, Peter04/01/202006/30/2022495176University of Melbourne (Melbourne University)The Lawrence and Isabel Barnett Drug Development Award
20-SI-544Accelerating the Path to Effective Treatments for ALS-Platform TrialCudkowicz, Merit01/01/202012/31/20223000000The General Hospital Corporation doing business as Massachusetts General HospitalStrategic Initiative
20-SI-539The ALS Association Clinical Trial Support Program-MGHCudkowicz, Merit01/01/202012/31/2022387658The General Hospital Corporation doing business as Massachusetts General HospitalStrategic Initiative
22-DDC-613GLP Studies on Antisense Oligonucleotide TherapiesElbaum, Daniel01/31/202201/30/2024500000.00QurAlis CorporationThe Lawrence and Isabel Barnett Drug Development Award
22-SI-602ALS Drug Rescue using a Novel Machine-Learning Based Subgroup Analysis ToolEnnist, David11/01/202101/31/2022100000.00Origent Data Sciences, Inc.Strategic Initiative
20-IIA-540Identification of Novel Targets that Regulate Stress Granules and Rescue Neurodegeneration in ALSFinkbeiner, Steve01/01/202006/30/2023300000Gladstone InstitutesInvestigator-Initiated Multi-year Award
22-CTA-610RAPA-501 Hybrid TREG/Th2 Cell Therapy of ALSFowler, Daniel01/01/202212/31/20231000000.00Rapa Therapeutics, LLCClinical Trial Awards
21-CRTF-577Feasibility and Patient/Caregiver Satisfaction of Telemedicine Visits for ALS ManagementGhasemia , Mehdi07/01/202006/30/2022105000.00Massachusetts General Hospital (The General Hospital Corporation), Boston, MAClinical Research Training Fellow
23-DDC-625TRPML1 small molecule agonists for the treatment of ALSGill, Martin10/01/202209/30/2024450272.00Libra Therapeutics, Inc.The Lawrence and Isabel Barnett Drug Development Award
22-PDF-592Molecular mechanisms influencing cognitive impairment in C9orf72 ALS/FTDGittings, Lauren07/01/202106/30/2023150000.00Dignity Health dba St. Joseph's Hospital & Medical Center, Phoenix, AZMilton Safenowitz Postdoctoral Fellowship Program
20-IIA-532ALS Gene and Environment InteractionsGoutman, Stephen12/01/201911/30/2022298676The Regents of the University of MichiganInvestigator-Initiated Multi-year Award
20-MALS-549Maximizing Social Connection in Persons with Speech Impairment Due to ALSGreen, Jordan01/31/202007/31/2022197087Massachusetts General Hospital-Institute of Health ProfessionsManaging ALS - MALS
20-SI-542Natural History Pilot Project-VCUGwathmey, Kelly01/01/202003/31/202125659.00Virginia Commonwealth UniversityStrategic Initiative
21-SI-570Natural History Pilot Project- St. Louis UniversityHayat, Ghazala02/01/202009/30/202025659.00Saint Louis UniversityStrategic Initiative
23-SGP-626Establishing an African ALS-research network to transform the ALS landscapeHeckmann, Jeannine10/01/202209/30/202350000.00University of Cape TownSeed Grants Program
21-SI-566Natural History Pilot Project- Temple UniversityHeiman-Patterson, Terry02/01/202012/31/202025659Temple UniversityStrategic Initiative
20-IIA-524Microbiome in Progression of ALSHertzberg, Vicki11/01/201902/28/2024299985.00Emory UniversityInvestigator-Initiated Multi-year Award
22-DDC-597Novel Protein Folding Gene Therapy for ALSHishiya, Akinori10/01/202109/30/2023500000.00Sola BiosciencesThe Lawrence and Isabel Barnett Drug Development Award
20-MALS-553Enabling independent home use of an intracortical brain-computer interface for control of multiple communication devicesHochberg, Leigh01/31/202006/29/2023200000.00Brown UniversityManaging ALS - MALS
21-SI-580Prognostic Value of miRNAs in biofluids from ALS patientsHornstein, Eran10/01/202005/31/202250000.00Weizmann Institute of ScienceStrategic Initiative
22-CTA-614Repurposing Enoxacin therapy for patients with ALSHornstein, Eran01/01/202212/31/2023750000.00Weizmann Institute of ScienceClinical Trial Awards
22-SI-603Neurofilament as a Fluid Biomarker of Neurodegeneration in f-FTD ProjectHorton, Wesley11/01/202110/31/2023140000.00Foundation for the National Institutes of Health, IncStrategic Initiative
20-IIA-529Countering the aggregation of TDP-43, FUS, DRPs, and Martin 3 with engineered protein disaggregasesJackrel, Meredith11/01/201912/31/2023300000.00Washington University in St.LouisInvestigator-Initiated Multi-year Award
22-PDF-604Smartphone-based Digital Phenotyping in People with ALSJohnson, Stephen10/01/202109/30/202275000.00Massachusetts General Hospital (Mass General)Milton Safenowitz Postdoctoral Fellowship Program
22-PDF-601Dysfunction and degeneration of corticospinal tract neurons in ALS mouse modelsKalambogias, John10/01/202109/30/2023150000.00The Trustees of Columbia University in the City of New YorkMilton Safenowitz Postdoctoral Fellowship Program
21-SI-584Sleep, stress and Caregiving: Young Caregivers in ALSKavanaugh, Melinda12/01/202008/31/202228624.00University of Wisconsin-MilwaukeeStrategic Initiative
21-SI-576Brainstorm BCT-002 US Biomarker ResearchKern, Ralph09/01/202005/31/2022500000.00Brainstorm Cell Therapeutics, IncStrategic Initiative
23-SEA-6202022 Sheila Essey Award for ALS ResearchKiernan, Matthew07/01/202206/30/202350000.00Neuroscience Research AustraliaSheila Essey Award
22-SI-600The role of circRNAs in the pathogenesis of motor neuron degenerationKing, Peter H.09/01/202108/31/2023100000.00University of Alabama at BirminghamStrategic Initiative
21-PDF-582The mechanism by which loss of stathmin-2 induces neurodegeneration in ALSKoike, Yuka01/31/202101/30/2023150000.00Mayo Clinic JacksonvilleMilton Safenowitz Postdoctoral Fellowship Program
21-CSDA-578Examining the role of ATM in selective vulnerability in ALSKreple , Collin07/01/202007/01/2022168000.00Washington University in St.LouisClinician Scientist Development Award
21-MALS-572A Mindful Community for People with ALS and their Primary CaregiversLanger, Ellen03/01/202004/30/2023200000.00President & Fellows of Harvard CollegeManaging ALS - MALS
20-DDC-533Validation of Efficacy for an Inhibitor of TDP-43 Pathology in the DNLS Mouse Model of ALSLarsen, Glenn12/01/201911/30/2020194343Aquinnah Pharmaceuticals IncThe Lawrence and Isabel Barnett Drug Development Award
22-DDC-606Preclinical evaluation of bemcentinib as a novel therapeutic for ALSLee, Virginia01/15/202201/14/2024500000.00Perelman School of Medicine, University of PennsylvaniaThe Lawrence and Isabel Barnett Drug Development Award
22-PDF-588Validating SYF2 suppression as a therapeutic strategy for diverse forms of ALSLi, Yichen02/01/202101/31/2023150000.00University of Southern California (USC)Milton Safenowitz Postdoctoral Fellowship Program
20-SI-537Natural History Pilot Project-NEMOLunetta, Christian01/01/202009/30/202025659.00Centro Clinico NEMOStrategic Initiative
21-PDF-564Unravelling shared molecular mechanisms in familial Amyotrophic Lateral SclerosisMarques, Christine02/01/202001/31/2022100000.00The General Hospital Corporation doing business as Massachusetts General HospitalMilton Safenowitz Postdoctoral Fellowship Program
21-PDF-587Longitudinal cognition and behavior in presymptomatic ALS gene mutation carriersMcHutchison, Caroline01/31/202101/30/2023148849.00University of EdinburghMilton Safenowitz Postdoctoral Fellowship Program
21-SI-579Establishing the Natural History of Upper Motor Neurondominant ALS and PLSMitsumoto, Hiroshi08/01/202007/31/2023220000.00The Trustees of Columbia University in the City of New YorkStrategic Initiative
20-IIA-531Identifying NK Cells as a Therapeutic Targets in ALSMurdock, Benjamin12/01/201902/28/2023300000The Regents of the University of MichiganInvestigator-Initiated Multi-year Award
20-IIA-546Discovery of novel phenotypes of amyotrophic lateral sclerosis based on neurophysiological measures of network dysfunction for patient stratification in clinical trialsNasseroleslami, Bahman01/01/202006/30/2023300000The Provost, Fellows, Foundation Scholars, and the other members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth near DublinInvestigator-Initiated Multi-year Award
20-SI-559HERV-K (HML-2) Suppression using Antiretroviral Therapy in Volunteers with ALSNath, Avindra01/01/202002/29/2024348556National Institute of Neurological Disorders and Stroke, NIH NINDSStrategic Initiative
20-SI-547Natural History Pilot Project-ProvidenceOlney, Nicholas01/01/202009/30/202025659.00Providence Health and Services- Oregon dba ProvidenceStrategic Initiative
22-PDF-605Pathomechanisms of ALS caused by SPTLC1 mutationsPant, Devesh01/15/202201/14/2024150000.00Emory UniversityMilton Safenowitz Postdoctoral Fellowship Program
21-PDF-585Pathogenic mechanisms of ALS caused by KIF5A mutationsParameswaran, Janani01/31/202101/30/2023150000.00Emory UniversityMilton Safenowitz Postdoctoral Fellowship Program
585-ClosedPathogenic mechanisms of ALS caused by KIF5A mutationsParameswaran, Janani01/31/202101/30/20230.00Emory UniversityMilton Safenowitz Postdoctoral Fellowship Program
20-IIA-525Harnessing the heterogenity of neuroinflammatory responses to tackle neurodegeneration in Amyotrophic Lateral SclerosisPeviani, Marco12/01/201911/30/2022276100Università di PaviaInvestigator-Initiated Multi-year Award
20-DDC-550Preclinical evaluations of a novel small molecule Toll-Like 2 receptor (TLR2) antagonist as a putative ALS therapeuticPrice, Diana01/31/202004/30/2022500000.00Neuropore Therapies, IncThe Lawrence and Isabel Barnett Drug Development Award
23-PDF-623Applying the human disaggregase, HtrA1, to counter Amyotrophic Lateral SclerosisPURI, ANURADHIKA08/01/202207/31/2024150000.00Washington University in St.LouisMilton Safenowitz Postdoctoral Fellowship Program
20-SI-536TDP43 Biomarker InitiativeRaisinghani, Manish01/01/202004/30/2021350000Target ALS FoundationStrategic Initiative
20-DDC-551Pre-clinical development of a Live Biotherapeutic Product used in the treatment of ALSReyes, Christopher01/31/202001/30/2022500000Bloom Science CoThe Lawrence and Isabel Barnett Drug Development Award
22-CTA-615Target NMJ to maintain motor functions in ALSRobitaille, Richard01/30/202201/29/2025996938.06Université de MontréalClinical Trial Awards
21-SI-581Development of ALS genetic testing guidelinesRoggenbuck, Jennifer12/01/202006/30/2022149188.00The Ohio State UniversityStrategic Initiative
20-PDF-527C9ORF72: Endobody vaccine for the treatment of C9 ALS/FTDRomano, Lisa11/01/201910/31/2021100000.00University of FloridaMilton Safenowitz Postdoctoral Fellowship Program
22-DDC-608ASO mediated knockdown of CHMP7 as a novel therapeutic strategy for ALS/FTDRothstein, Jeffrey01/01/202212/31/2023494444.00Johns Hopkins University School of MedicineThe Lawrence and Isabel Barnett Drug Development Award
21-SEA-575Sheila Essey Award 2020Rouleau , Guy05/21/202005/20/202150000.00Montreal Neurological Hospital and InstituteSheila Essey Award
22-CSDA-594Lysosomal Protease Dysfunction in Amyotrophic Lateral SclerosisSampognaro, Paul07/01/202106/30/2024168000.00The Regents of the University of California, San FranciscoClinician Scientist Development Award
21-SI-573Renewal for 16-LGCA-311, Integrated genomics in clinical AKS: PBMC library generationSareen, Dhruv03/01/202003/31/202139990Cedars-Sinai Medical CenterStrategic Initiative
22-DDC-607Antagonism of RAGE/DIAPH1 and Therapies for Amyotrophic Lateral SclerosisSchmidt, Ann Marie01/01/202212/31/2023500000.00New York University Grossman School of MedicineThe Lawrence and Isabel Barnett Drug Development Award
22-PDF-590Ten finger typing using an intra-cortical implant for fast communication in ALSShah, Nishal02/01/202101/31/2023150000.00The Board of Trustees of the Leland Stanford Junior UniversityMilton Safenowitz Postdoctoral Fellowship Program
20-SI-552The ALS Association Clinical Trial Support Program-BNIShefner, Jeremy01/01/202012/31/2022264885Dignity Health dba St. Joseph's Hospital & Medical Center, Phoenix, AZStrategic Initiative
23-CRTF-6192022 Clinical Research Training ScholarshipShellikeri, Sanjana07/01/202206/30/2024105000.00Perelman School of Medicine, University of PennsylvaniaClinical Research Training Fellow
20-SI-535ALS Focus PlatformSherman, Alexander01/01/202006/30/2021304669.00The General Hospital Corporation doing business as Massachusetts General HospitalStrategic Initiative
20-SI-541Natural History Pilot Project-MGHSherman, Alexander01/01/202006/30/202044240The General Hospital Corporation doing business as Massachusetts General HospitalStrategic Initiative
21-SI-567The Pooled Resource Open Access ALS Clinical Trials (Pro-Act) DatabaseSherman, Alexander02/01/202001/31/20231262129The General Hospital Corporation doing business as Massachusetts General HospitalStrategic Initiative
22-SI-596ALS FOCUS Program, Surveys, Maintenance, and SupportSherman, Alexander07/01/202108/31/2023263050.00Massachusetts General Hospital (Mass General)Strategic Initiative
20-SI-557Expanded Access to the FUS-ASO, Jacifusen for the Treatment of Mutant FUS-Associated ALSShneider, Neil01/01/202012/31/2022650000.00The Trustees of Columbia University in the City of New YorkStrategic Initiative
20-IIA-534Antagonizing neurotoxic phase transitions of TDP-43 and FUS with small RNA therapeuticsShorter, James12/01/201902/28/2023300000The Trustees of the University of PennsylvaniaInvestigator-Initiated Multi-year Award
20-MALS-554Respiratory Health Management in Amytrophic Lateral Sclerosis through Telemonitoring and Nurse Health CoachingSimmons, Zachary01/31/202007/31/2023197302.00The Pennsylvania State UniversityManaging ALS - MALS
22-CTA-611Acute adenosine receptor antagonism to promote breathing plasticity in ALSSmith, Barbara01/01/202212/31/2024880826.00University of FloridaClinical Trial Awards
22-PDF-591Family-based self-compassion intervention for reducing self-stigma in ALSSommers-Spijkerman, Marion07/01/202106/30/2023150000.00University Medical Center UtrechtMilton Safenowitz Postdoctoral Fellowship Program
23-SI-616Establishing causative roles for SARM1 coding & expression level variants in ALSSreedharan, Jemeen03/01/202208/31/2024400000.00King's College London, Institute of PsychiatryStrategic Initiative
21-SI-586Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for ALSSTAFF, NATHAN01/31/202112/31/2023252000.00Mayo Clinic RochesterStrategic Initiative
22-DDC-598Development of a matrix metalloproteinase inhibitor for the treatment of ALSSucholeiki, Irving10/01/202107/31/2023500000.00Aquilus Pharmaceuticals, Inc.The Lawrence and Isabel Barnett Drug Development Award
22-SI-589Maintain the SOD1 breeding colony in 2021Torvund-Jensen, Julie02/01/202101/31/2022145800.00Taconic Biosciences, Inc.Strategic Initiative
23-SI-617Maintain the SOD1 breeding colony in 2022Torvund-Jensen, Julie02/01/202201/31/2023343410.00Taconic Biosciences, Inc.Strategic Initiative
20-IIA-526ALS Patient Progression Tracking Mobile App vs Clinical Data CollectionTyler, Chris12/01/201911/30/2022300000ALS Never Surrender FoundationInvestigator-Initiated Multi-year Award
21-PDF-583Determining mechanisms of TDP-43 liquid-liquid phase separation and aggregationVazquez-Sanchez, Sonia01/31/202101/30/2023150000.00Ludwig Instituite for Cancer ResearchMilton Safenowitz Postdoctoral Fellowship Program
22-SEA-593Sheila Essey Award 2021Veldink, Jan04/21/202104/20/202250000.00University Medical Center UtrechtSheila Essey Award
20-SI-558Natural History Pilot Project- University of MinnesotaWALK, DAVID01/01/202010/31/202025659.00Regents of the University of Minnesota - Twin CitiesStrategic Initiative
20-MALS-538Eye gaze-based technology using Apple TrueDepth camera to enable communication for ALS patientsWang, Fusheng01/31/202007/31/2022199998State University of New York, Stony BrookManaging ALS - MALS
20-SI-560Natural History Pilot Project- University of FloridaWymer, James01/01/202006/30/202025659.00University of FloridaStrategic Initiative
20-IIP-556Developing Chemically Induced Senescence to Model ALS Pathogenesis Using iPSCsZhang, Su Chun01/31/202004/30/202150000.00University of Wisconsin-Madison (Board of Regents University of Wisconsin System)Investigator-Initiated Starter Award